Makena Pricing Prompts Multi-Pronged Appeals: FDA, FTC – Bayh-Dole?

The uproar among insurers, physicians and patient groups over the relatively high price of KV Pharmaceutical’s new injectable treatment for preventing preterm births, Makena, has elicited appeals to FDA and the Federal Trade Commission for intervention.